An Introduction to Respiratory
Asthma is a chronic inflammatory disorder of the airwaves and one of the most common respiratory diseases. While the majority of cases can be controlled, severe asthma is associated with high risk of exacerbations and death. Severe asthma is categorised as T-helper type 2 (T2) high and T2 low. T2 high, also known as eosinophilic asthma, involves generation of cytokines including interleukin-4, −5 and −13. Recently, the management of severe eosinophilic asthma has been transformed by the development of monoclonal antibodies. Other allergic respiratory diseases include allergic rhinitis, which can be managed via symptomatic treatment with antihistamines, and allergy immunotherapy.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Improving outcomes in severe paediatric asthma: New treatments, new possibilities
Watch an asthma expert and a primary care respiratory specialist discuss diagnosis, treatment and management of severe asthma in children.
- Recall the symptoms associated with severe asthma in children
- Summarize the clinical evidence supporting the use of biologics in children with severe asthma
- Describe the optimal long-term management of children with severe asthma
Minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis
Watch ENT specialists discuss key considerations in optimizing the management of patients with CRSwNP.
- Describe the burden of disease of CRSwNP and the importance of early diagnosis
- Explain the pathophysiology of CRSwNP and how this can guide treatment decisions
- Summarize the clinical evidence supporting the use of current and emerging treatment options for CRSwNP
Strategies for the management of severe type 2 asthma: Expert insight into optimizing care
MDT specialists, plus a patient with severe asthma, discuss the disease burden and the role of biologics in the long-term management of severe T2 asthma
- Recognize the challenges associated with living with severe asthma
- Discuss the role of biomarkers in guiding biologic treatment selection for patients with severe T2 asthma
- Recall evidence-based guidance on the long-term management of patients with severe T2 asthma
Unravelling endotypes for treatment selection in severe type 2 asthma
Experts discuss how endotyping and biomarkers can help to guide optimal treatment selection in patients severe type 2 asthma
- Recall key data on the serious consequences of severe type 2 asthma
- Summarize severe asthma endotypes and the corresponding selection of biological therapies
- Evaluate the most recent evidence on key aspects of long-term management of patients with severe type 2 asthma
Strategies for the management of chronic rhinosinusitis with nasal polyps: Expert insight in optimizing care
Watch a panel of experts discuss challenges in the diagnosis of CRSwNP and considerations for optimal management of the disease.
- Define diagnostic criteria for CRSwNP
- Recognize that eosinophilic inflammation in CRSwNP is a predictor of disease recurrence
- Outline advancements in the treatment of CRSwNP
Luis Puente-Maestu, ERS 2021: The Phase 3 Study of MV130
It was a pleasure to meet with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) to explore the efficacy and safety findings from the phase 3 study of MV130 for the prevention of COPD exacerbations. The abstract ‘Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD […]
Luis Puente-Maestu, ERS 2021: MV130 Immunotherapy to Prevent COPD Exacerbations
It was great to talk with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) around the abstract ‘Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations.’ (Presentation ID 207), which was presented at ERS International Congress 2021, 5-8 September 2021. Questions What is known about […]
Eosinophilic inflammatory diseases of the respiratory system: New therapeutic options
Watch a panel of experts discuss how to identify and manage patients with inflammatory respiratory diseases, with a focus on severe eosinophilic asthma.
- Recognize the role of eosinophils and type 2 inflammation in respiratory disease
- Understand the diagnostic methods used to differentiate inflammatory diseases of the respiratory system
- Recall disease states that may benefit from therapies that target the complex interaction between eosinophils and their environment
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
Watch a panel of experts discuss the diagnosis of type 2 asthma, the rationale for biological therapy and emerging treatments.
- Recognize the importance of biomarkers to identify patients with type 2 asthma accurately and promptly
- Outline the pathologic pathways underlying type 2 asthma and the differing mechanisms of action of available biologic therapies
- Recall the latest data for biologic therapies in moderate-to-severe type 2 asthma
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!